Area of Focus: Oncology

Fusix is a preclinical-stage biotech spinout from the Technical University of Munich. With strong scientific foundations, we are developing transformative therapies that enhance immune responses and therapeutic efficacy in cancer by reshaping the tumor microenvironment to overcome known resistance mechanisms. Our mission is to bridge the gap between scientific innovation and real-world impact to redefine immune oncology. Our lead candidate is on track to enter the clinical stage in 2027.